N-(4-(6-(4-chlorophenethoxy)pyridazin-3-yl)phenyl)-1,1,1-trifluoromethanesulfonamide | 1252918-05-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: N-(4-(6-(4-chlorophenethoxy)pyridazin-3-yl)phenyl)-1,1,1-trifluoromethanesulfonamide
• 英文别名: N-[4-[6-[2-(4-chlorophenyl)ethoxy]pyridazin-3-yl]phenyl]-1,1,1-trifluoromethanesulfonamide
• CAS: 1252918-05-0
• 化学式: C₁₉H₁₅ClF₃N₃O₃S
• 分子量: 457.861
• InChiKey: JKVHAITWTGCIRS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  30
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  89.6
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  三氟甲烷磺酰氯 、 4-(6-(4-chlorophenethoxy)pyridazin-3-yl)aniline 在 吡啶 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 N-(4-(6-(4-chlorophenethoxy)pyridazin-3-yl)phenyl)-1,1,1-trifluoromethanesulfonamide
  参考文献：
  名称：

  [EN] COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES
  [FR] COMPOSÉS, COMPOSITIONS ET MÉTHODES COMPRENANT DES DÉRIVÉS DE PYRIDAZINE SULFONAMIDE

  摘要：

  本发明涉及用于治疗动物的疾病的组合物和方法，所述疾病对通过向需要它的哺乳动物施用本发明定义的有效量的化合物（包括表1-3中列出的或由公式I-III涵盖的化合物）或其组合物从而抑制功能性囊性纤维化跨膜电导调节器（CFTR）多肽的治疗有响应。特别是，本发明涉及治疗腹泻和多囊肾疾病的方法。

  公开号：

  WO2010123822A1

文献信息

• Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives
  申请人：de Hostos Eugenio L.

  公开号：US20110288093A1

  公开（公告）日：2011-11-24

  The present invention relates to methods for treating a disease in an animal, which disease is responsive to blocking of chloride channel by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Tables 1-3 or encompassed by formula I-III) or compositions thereof

  本发明涉及一种治疗动物疾病的方法，该疾病对通过给需要该药物的哺乳动物施用本文定义的化合物（包括表1-3中列出的化合物或公式I-III所包含的化合物）或其组合物阻断氯离子通道产生反应的有效量敏感。
• COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES
  申请人：Penrose Stephen David

  公开号：US20120129858A1

  公开（公告）日：2012-05-24

  The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Tables 1-3 or encompassed by formula I-III) or compositions thereof, thereby treating the disease. The present invention particularly, relates to a method of treating diarrhea and polycystic kidney disease.

  本发明涉及用于治疗动物疾病的组合物和方法，该疾病对通过给予需要的哺乳动物有效量的本文中定义的化合物（包括表1-3中列出的化合物或公式I-III所包含的化合物）或其组合物抑制功能性囊性纤维化跨膜传导调节因子（CFTR）多肽敏感，从而治疗该疾病。本发明特别涉及一种治疗腹泻和多囊肾病的方法。
• [EN] COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES<br/>[FR] COMPOSÉS, COMPOSITIONS ET MÉTHODES IMPLIQUANT DES DÉRIVÉS SULFAMIDÉS DE PYRIDAZINE
  申请人：INST ONEWORLD HEALTH

  公开号：WO2011133600A1

  公开（公告）日：2011-10-27

  The present invention relates to methods for treating a disease in an animal, which disease is responsive to blocking of chloride channel by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Tables 1-3 or encompassed by formula I-III) or compositions thereof.
• [EN] COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES<br/>[FR] COMPOSÉS, COMPOSITIONS ET MÉTHODES COMPRENANT DES DÉRIVÉS DE PYRIDAZINE SULFONAMIDE
  申请人：INST ONEWORLD HEALTH

  公开号：WO2010123822A1

  公开（公告）日：2010-10-28

  The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Tables 1-3 or encompassed by formula I-III) or compositions thereof, thereby treating the disease. The present invention particularly, relates to a method of treating diarrhea and polycystic kidney disease.

  本发明涉及用于治疗动物的疾病的组合物和方法，所述疾病对通过向需要它的哺乳动物施用本发明定义的有效量的化合物（包括表1-3中列出的或由公式I-III涵盖的化合物）或其组合物从而抑制功能性囊性纤维化跨膜电导调节器（CFTR）多肽的治疗有响应。特别是，本发明涉及治疗腹泻和多囊肾疾病的方法。